CMIC Supports Avigan Production for Potential COVID-19 Treatment

CMIC Holdings Co., Ltd. said its affiliate, CMIC Co., Ltd., a contract research organization (CRO) in Japan, is providing monitoring services for Avigan Tablet (favipiravir), a product that Fujifilm Toyama Chemical Co., Ltd. gained approval in Japan for manufacture and sale as an influenza antiviral drug, phase III clinical trial in Japan and will support for manufacturing the product as a contract development and manufacturing organization (CDMO).
 
Recently, Fujifilm announced the start of clinical trials of Avigan in Japan and overseas as one of the drug candidates for COVID-19. In addition, the Japanese government plans to stockpile two million treatment courses of Avigan, as part of the Japanese government's emergency economic package.
 
Also, CMIC CMO Co., Ltd., a CDMO in Japan, will manufacture Avigan Tablet at their main plant to contribute to Fujifilm’s accelerated production schedule.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.